PMC7879677_01
(A) The patient under mycophenolate-mofetil 2 g/day and topical corticosteroids (before therapy with dupilumab and omalizumab), (B) 2 months after addition of omalizumab therapy to his therapy protocol, (C) stable clinical results, 3 months after addition of dupilumab to his therapy protocol.
fimmu-11-611549-g001.jpg
PMC7879677_01_fimmu-11-611549-g001.jpg
f1
Three months later, the patient remained in complete remission on combination of omalizumab and dupilumab with no clinical or biological side effects and ELISA-BP180 levels remained stable (24.8 U/ml). ( Figures 1 ,  2 ).
Histopathological image of the lesions, which is compatible with urticarial dermatitis with presence of ulceration and eosinophils.
fimmu-11-611549-g002.jpg
PMC7879677_01_fimmu-11-611549-g002.jpg
f2
Three months later, the patient remained in complete remission on combination of omalizumab and dupilumab with no clinical or biological side effects and ELISA-BP180 levels remained stable (24.8 U/ml). ( Figures 1 ,  2 ).